SEC Form 4 · accession 0000897204-18-000027
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francesco Micheli
10% Owner
Period of report
Apr 9, 2018
Accepted (ET)
Apr 9, 2018 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per shareF1,F2 | Apr 9, 2018 | P | 390,625 | $64.00 | A | 6,845,578 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock purchased by Genextra S.p.A. in a private offering that was completed on April 9, 2018.
- F2These shares are held by Genextra S.p.A. Mr. Micheli is the Executive Director and Chairman of the board of Genextra S.p.A. and, in such capacity, Mr. Micheli exercises voting control over the shares of common stock owned by Genextra S.p.A and investment control over such shares as authorized by the board of Genextra S.p.A. Mr. Micheli disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.